SCHEDULE: Vanguard Group Discloses 10.04% Stake in Myriad Genetics

The Vanguard Group has filed an amended Schedule 13G, reporting a 10.04% beneficial ownership stake in Myriad Genetics Inc. as of June 30, 2025.

Summary

• The Vanguard Group reported beneficial ownership of 9,257,493 shares of Myriad Genetics Inc. common stock.
• This represents 10.04% of the class of securities.
• Vanguard holds sole dispositive power over 9,003,551 shares and shared dispositive power over 253,942 shares.
• Shared voting power is held over 145,939 shares, with no sole voting power.
• The filing is an Amendment No. 12 to a Schedule 13G, indicating a change in ownership from a previous filing.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The filing indicates a significant and passive institutional investment by The Vanguard Group, which is generally viewed positively as it suggests long-term confidence in the company without intent to disrupt control. No negative information is presented.

Positives

• Significant institutional ownership by The Vanguard Group, a major investment firm, indicates confidence in Myriad Genetics Inc.
• The 10.04% stake suggests a substantial, long-term investment by a passive investor.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Myriad Genetics Inc.'s future performance or outlook.

Industry Context

This filing reflects a major institutional investor's continued or increased stake in Myriad Genetics Inc., a company operating in the healthcare and diagnostics industry. Such significant passive ownership by a firm like Vanguard is common across various industries and typically signals a long-term investment strategy rather than an active attempt to influence company operations.

Stakeholder Impact

• Shareholders: Increased institutional ownership by a major firm like Vanguard can enhance investor confidence and potentially contribute to stock stability.

Key Dates

Recommendation

The filing indicates a substantial, passive stake by a major institutional investor, The Vanguard Group, which suggests long-term confidence in Myriad Genetics Inc. without any intent to influence control. While this is a positive signal, the filing itself does not provide new operational or financial performance data to warrant a 'buy' or 'sell' recommendation. It primarily confirms a significant existing or slightly adjusted institutional position, supporting a 'hold' stance for investors already in or considering the stock, as it reinforces the company's stability from an ownership perspective.

Keywords

Myriad Genetics Inc., Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Equity Stake, Investment Adviser